ArticleNeuropsychopharmacology reports2025
Clinical Characteristics of Patients With Cannabis-Related Mental Disorders and an Examination of Factors Influencing Their Access to Medical and Nonmedical Resources: Comparison of Methamphetamine-Related Mental Disorders.
Article in Neuropsychopharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profiles.PCN reports : psychiatry and clinical neurosciences · 2026Review
- Clinical Characteristics of Patients With Cannabis-Related Mental Disorders and an Examination of Factors Influencing Their Access to Medical and Nonmedical Resources: Comparison of Methamphetamine-Related Mental Disorders.Neuropsychopharmacology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study aims to identify the characteristics of patients with cannabis use disorder and to determine whether the challenges in treating cannabis use disorder stem from the pharmacological properties of cannabis as an abused substance or from other contributing factors.
methodsThe subjects of this study were the 208 male cases of methamphetamine-related mental disorders (MAP group) and 82 male cases of cannabis-related mental disorders (CAN group), which drawn from the "2024 Nationwide Survey on the Actual Conditions of Drug-Related Mental Disorders in Psychiatric Hospitals in Japan." Clinical variables were compared between the two groups, and logistic regression analyses were conducted to examine the use of medical and nonmedical resources.
resultsThe CAN group was found to be younger, to have fewer histories of drug-related criminal offenses, incarceration in correctional facilities, or comorbid psychiatric disorders, compared to the MAP group, and to exhibit less severe forms of substance use disorder and have less experience participating in self-help groups or utilizing private recovery support facilities. Logistic regression analyses of the use of self-help groups and private recovery support facilities indicated that the utilization of these nonmedical resources was more strongly associated with older age and greater severity of substance use disorder than with the specific type of substance abused.
conclusionRecently, an increasing number of young patients in Japan have been arrested for cannabis-related offenses and seek addiction treatment. There is growing concern that current nonmedical support resources may not adequately address the specific needs of these individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.